Form 4: Alumis Chief Legal Officer Granted Significant Equity Awards

Alumis Inc.'s Chief Legal Officer, Sanam Pangali, was granted 10,000 restricted stock units and options to purchase 40,000 shares of common stock, aligning executive incentives with long-term company performance.

Summary

• Sanam Pangali, Chief Legal Officer of Alumis Inc., acquired 10,000 shares of common stock through a Restricted Stock Unit (RSU) grant on July 29, 2025.
• The RSU grant has a vesting schedule where 25% of the shares vest on August 1, 2026, with the remaining shares vesting in equal quarterly installments over the subsequent 12 quarters (3 years), contingent on continuous service.
• Additionally, Ms. Pangali was granted stock options to acquire 40,000 shares of common stock with an exercise price of $3.95 per share on July 29, 2025.
• The stock options vest 25% on July 29, 2026, and the remaining shares vest in equal monthly installments over the following 36 months (3 years), also subject to continuous service.
• Following these transactions, Ms. Pangali beneficially owns 11,111 shares of common stock and 40,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a significant equity grant to a key executive, which is generally a positive signal as it aligns management's long-term interests with shareholders and incentivizes retention and performance. It is a routine disclosure but reflects confidence in the executive and the company's future.

Positives

• The grant of restricted stock units and stock options to a key executive like the Chief Legal Officer aligns management's interests with long-term shareholder value creation.
• Equity awards serve as a strong incentive for executive retention and performance, encouraging continued dedication to the company's success.

Risks

• The value of the equity awards is subject to the future performance of Alumis Inc.'s common stock, meaning the actual realized value could be lower than the current implied value if the stock price declines.
• Vesting of both RSUs and stock options is contingent upon the Reporting Person's 'Continuous Service' to the Issuer, meaning the awards could be forfeited if employment ceases before vesting dates.

Future Outlook

The filing details future vesting schedules for the granted equity awards, indicating that a significant portion of the Chief Legal Officer's compensation is tied to the company's long-term performance and her continued service through August 2026 and beyond for the RSUs, and July 2026 and beyond for the stock options.

Industry Context

This filing is a standard disclosure of executive equity compensation, a common practice across publicly traded companies in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key talent. Such grants are a typical component of a comprehensive executive compensation package aimed at aligning leadership interests with shareholder returns.

Comparison to Industry Standards

• The structure of equity grants, including a mix of Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules, is consistent with common executive compensation practices observed in the biotechnology and pharmaceutical industries.
• The vesting periods of 3-4 years for the full awards are standard for long-term incentive plans designed to promote executive retention and sustained performance, comparable to practices at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals for their senior executives.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Legal Officer's financial interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: The grants demonstrate the company's commitment to incentivizing and retaining key talent, which can positively impact overall employee morale and stability.
• Management: The awards provide significant long-term incentives and compensation, encouraging continued dedication and performance.

Next Steps

• Continued vesting of 25% of RSUs on August 1, 2026, and remaining shares in equal quarterly installments over the following 12 quarters.
• Continued vesting of 25% of stock options on July 29, 2026, and remaining shares in equal monthly installments over the following 36 months.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a positive signal for management alignment and retention. However, it does not contain information about the company's operational performance, financial results, or strategic developments that would warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for investors who are already invested or considering the stock, as it indicates stable corporate governance and incentive structures without providing new fundamental performance data.

Keywords

Alumis Inc., ALMS, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Chief Legal Officer, Sanam Pangali